Velufenacin
Tier C — Watch / tradeVelufenacin
Targets：CHRM3
Indications (approved)：Overactive bladder, Renal impairment
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| DA-8010 | 1648737-78-3 | (R)-(1-methylpyrrolidin-3-yl)methyl (3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate |
| DA-8010-001 | 88-65-3 | 2-bromobenzoic acid |
| DA-8010-002 | 138108-72-2 | tert-butyl (R)-3-(hydroxymethyl)pyrrolidine-1-carboxylate |
| DA-8010-003 | 1648738-76-4 | tert-butyl (R)-3-((((2-bromophenyl)carbamoyl)oxy)methyl)pyrrolidine-1-carboxylate |
| DA-8010-004 | 1648738-77-5 | (R)-pyrrolidin-3-ylmethyl (2-bromophenyl)carbamate |
| DA-8010-005 | 1648738-75-3 | (R)-(1-methylpyrrolidin-3-yl)methyl (2-bromophenyl)carbamate |
| DA-8010-006 | 144432-85-9 | (3-chloro-4-fluorophenyl)boronic acid |
Frequently asked questions
What are the approved indications of Velufenacin?
Approved indications include: Overactive bladder, Renal impairment.
When does the Velufenacin patent expire?
No public expiry year is available for Velufenacin yet; this page updates once verified.
How many synthesis routes are recorded for Velufenacin?
1 synthesis routes are recorded; the shortest is 4 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Velufenacin intermediates?
All intermediates in Velufenacin routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Velufenacin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05